![]() | |
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C13H17NO |
Molar mass | 203.28 g/mol (freebase) 239.78 g/mol (hydrochloride) g·mol−1 |
3D model (JSmol) | |
| |
|
5-MBPB (also known as 5-MPBP and 5-MABB) is an amphetamine derivative which is structurally related to MDMA and has been sold as a designer drug. It can be described as the benzofuran-5-yl analogue of MBDB or the butanamine homologue of 5-MAPB, and is also a structural isomer of 5-EAPB and 6-EAPB. Anecdotal reports suggest this compound has been sold as a designer drug in various European countries since early 2015, but the first definitive identification was made in December 2015 by a forensic laboratory in Slovenia.[1]
5-MBPB is similar in structure to compounds such as 5-APB which are claimed to be agonists of the 5-HT2C receptor.[2]
References
- ^ European Monitoring Center for Drugs and Drug Addiction – Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA
- ^ US patent 7045545, Karin Briner et al, "Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists", published 2000-01-19, issued 2006-16-03